P/OSPeptideOS evidence & status map
OPEN SOURCE MEDICINE FOUNDATIONLast reviewed 2026-10-10No dosing · no vendors · no advicesource file

← All compounds · evidence tier first, by design

Evidence tier for each claimed use · ← established · unknown →
UseE1E2E3E4E5E6E7E8
E3 Chronic skin wounds and ulcers (full-length thymosin beta-4, not TB-500)E3
E6 Injury recovery: tendon, ligament, muscle and skin wounds (TB-500 fragment itself)E6
Class C · Gray market

TB-500

LKKTETQ

Seven residues corresponding to positions 17-23 of mature thymosin beta-4 (the actin-binding region). An anti-doping analysis identified the N-terminally acetylated form (Ac-LKKTETQ) in a product sold as TB-500; FDA names the substance 'thymosin beta-4, fragment (LKKTETQ), also known as TB-500'. The content of other products sold under this name was not assessed.

Also: TB500, Thymosin beta-4 fragment (LKKTETQ), Ac-LKKTETQ

A synthetic seven-amino-acid fragment of thymosin beta-4, a 43-residue protein found in most human cells. It is often marketed as if it were thymosin beta-4 itself, with claims of faster recovery from tendon, ligament and muscle injuries and wound healing. Research on the full-length protein does not transfer automatically to the fragment. TB-500 is not approved as a medicine in any jurisdiction checked. FDA states it has identified no human exposure data for it, and the World Anti-Doping Agency names it as prohibited.

  • US C gray market
  • EU ? not verified
  • UK ? not verified
  • CA ? not verified
  • AU ? not verified
  • JP ? not verified
  • CN ? not verified

01Regulatory status, by jurisdiction

Standing notice. This compound is not approved as a medicine in any jurisdiction tracked here and has no active sponsor seeking approval. Material sold under this name, typically labelled “research chemical, not for human consumption”, is of unverified identity and purity and is not manufactured to pharmaceutical standards.
JurisdictionStatusDetail and primary source
USNot approvedNot approved: FDA has approved no product containing TB-500. FDA's list of bulk substances that may present significant safety risks names 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' among substances previously in 503A Category 2 whose nominations were withdrawn; it is not on the current 503A Category 1 or 2 lists (updated 14 May 2026). FDA cites possible immunogenicity due to aggregation and peptide-related impurities.
“FDA has not identified any human exposure data drug products containing Thymosin Beta-4, Fragment. FDA lacks important information regarding any safety issues raised by this drug, including whether it would cause harm if administered to humans.”
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (FDA, content current as of 04/22/2026) · retrieved 2026-10-10
EU UK CA AU JP CNNot yet verified from a primary source. No status is shown rather than an unsourced one.

Sport (WADA): Prohibited · class S2.3. “Thymosin-ß4 and its derivatives e.g. TB-500” WADA source

02What the human evidence shows

E3

Chronic skin wounds and ulcers (full-length thymosin beta-4, not TB-500)

1published human RCTs
n/cpublished human trials
18registered studies
8with posted results

n/c: not counted here; see the cited review.

This row concerns full-length thymosin beta-4, a different molecule from TB-500, and is shown because marketing cites this research. A double-blind, placebo-controlled, dose-escalation phase 2 trial of topical thymosin beta-4 in 73 patients with venous leg ulcers across eight European sites reported safety comparable to placebo; the efficacy findings were described only as suggestive, and no confirmatory trial was identified. No trial has tested injected full-length thymosin beta-4 for tendon, ligament or muscle injury.

  • [1] Topical full-length thymosin beta-4 was tolerated similarly to placebo in 73 patients with venous ulcers; efficacy reported as suggestive, not confirmed
  • [2] Full-length thymosin beta-4 increased wound re-epithelialisation and contraction in a rat full-thickness wound model

Registered-study counts: ClinicalTrials.gov intervention search “thymosin beta 4”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.

E6

Injury recovery: tendon, ligament, muscle and skin wounds (TB-500 fragment itself)

No human trial of any design has been published for this use.

0published human RCTs
0published human trials
1registered studies
0with posted results

The only efficacy study of the fragment identified was in mice: the synthetic seven-residue peptide LKKTETQ gave dermal wound-repair results in aged mice comparable to full-length thymosin beta-4. No study of the fragment in tendon, ligament or muscle injury models was identified. No published human trial of TB-500 exists. A phase 1/2 trial of the fragment for cardiovascular biomarkers was registered in China in 2026 and is recruiting, with no results; it does not address injury recovery.

  • [3] The synthetic fragment LKKTETQ increased dermal wound closure in aged mice to a degree comparable with full-length thymosin beta-4

Registered-study counts: ClinicalTrials.gov intervention search “TB-500”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.

Key registered trials

NCTTitle (as registered)PhaseStatus
NCT07487363TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD1/2Recruiting

03Safety signals

S5No human safety data

There are no adequate human safety data. The absence of reported harm is not evidence of safety.

04What is unknown

  • No published human data on TB-500 of any kind: no pharmacokinetics, no safety and no efficacy by any route
  • No study of the fragment in tendon, ligament or muscle injury models was identified; claims for these uses rest on extrapolation from the full-length protein or from skin wounds in mice
  • Immunogenicity is unassessed; FDA states compounded TB-500 may pose a risk of immunogenicity due to aggregation and peptide-related impurities
  • What products sold as TB-500 actually contain (the acetylated fragment, the free fragment, full-length thymosin beta-4 or other material) was not assessed for this record
  • Regulatory status outside the US was not verified from regulator sources for this record

05Product quality

No independent purity results have been published for this compound yet. The purity programme will publish full methods and vendor-named results, passes and failures, once its protocol has had legal review.

06Citations

  1. The effect of thymosin treatment of venous ulcers (2010). doi:10.1111/j.1749-6632.2010.05490.x
  2. Thymosin β4 Accelerates Wound Healing (1999). doi:10.1046/j.1523-1747.1999.00708.x
  3. Thymosin β4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice (2003). doi:10.1046/j.1524-475x.2003.11105.x

Every DOI is resolved against Crossref and every NCT number against ClinicalTrials.gov, title for title, before publication. Regulatory sources are cited inline above with a verbatim quote and retrieval date.

07Mechanism

TB-500 corresponds to the actin-binding region of thymosin beta-4, a protein that sequesters monomeric actin inside cells; in aged mice the free fragment increased dermal wound closure.

Mechanism is placed last on purpose: a plausible mechanism is not evidence that a compound works in people.

Reviewed by OSMF research team (AI-assisted, source-verified) on 2026-10-10. Found an error? It goes in the corrections log: report it.